A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up

Table 2

Comparison of blood fluctuation, oxidative stress, and inflammatory profile within groups.

	Dulaglutide			Glimepiride
	Baseline	26 weeks after treatment		Baseline	26 weeks after treatment
FBG (mmol/L)			<0.001			0.005
HbA1c (%)			<0.001			0.008
Body weight (kg)			0.704			0.22
MBG (mmol/L)			0.001			0.009
SDBG (mmol/L)			0.026			0.857
MAGE (mmol/L)			0.298			0.686
MODD (mmol/L)			0.336			0.075
(mmol/L)	0 (0, 0)	0 (0, 0)	0.511	0 (0, 0)	0 (0, 0)	1
(mmol/L)	0 (0, 0)	0 (0, 0)	0.511	0 (0, 0)	0 (0, 0)	0.739
PT in 2.8-10 (mmol/L)	36 (4, 59.5)	72 (47, 89)	0.007	16 (7.25, 57.5)	77.5 (64.25, 89.75)	<0.001
PT in 3.9-10 (mmol/L)	36 (4, 59.5)	71 (41.5, 79)	0.026	16 (7.25, 57.5)	77.5 (64.25, 88.25)	<0.001
(mmol/L)	64 (40.5, 96)	28 (8, 53)	0.007	84 (42.5, 92.75)	22.5 (10.25, 35.75)	<0.001
(mmol/L)	27 (2.5, 63)	5 (0, 10.5)	0.019	16.5 (0.75, 37.5)	0 (0, 8.75)	0.035
TNF-α (pg/mL)			0.001			0.001
IL-6 (pg/mL)			<0.001			0.003
8-iso-PGF2α (pg/mL)			0.008			0.002

Abbreviations: FBG: fasting blood glucose; HbA1c: glycosylated hemoglobin; MBG: Mean Blood Glucose; SDBG: Standard Deviation of Blood Glucose; MAGE: Mean Amplitude of Glycemic Excursion; MODD: Absolute Means of Daily Difference; PT: percentage time; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; 8-iso-PGF2α: 8-iso-prostaglandin F2α. Data shown as or median (first quartile and third quartile).